Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
18500
¥ million (increase at the lower end of the full-year operating income forecast range)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary Materials to the Earnings SummarySecond quarter of the fiscal year ending March 20277 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales509,593 Millions of yen+12.2%
Operating profit84,962 Millions of yen+84.2%
Net income52,146 Millions of yen+78.7%
Selling, general and administrative expenses251,126 Millions of yen
Gross Profit Margin
Rate68.3%
Year-on-year change (points)3.1
Operating profit margin
Rate16.7%
Year-on-year change (points)6.5
Results for the three months of the current quarter
Net Sales
269,193 Millions of yen
Operating profit
56,011 Millions of yen
Pretax profit
55,045 Millions of yen
Net income
33,044 Millions of yen
Full-year earnings forecast
Net Sales¥1,064,500–¥1,076,000 million
Operating profit¥155,000–¥167,500 million
Adjusted operating profit¥186,500–¥199,000 million
Pretax profit¥150,000–¥162,500 million
Net income¥103,500–¥112,000 million
EBITDA¥223,000–¥235,500 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Foreign exchange impact on revenue
41,867 Millions of yen
Foreign exchange impact on operating profit
14,889 Millions of yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Average exchange rateUS$1=¥155.00, €1=¥181.00, CNY1=¥22.50
Key KPIsA metric the company considers important as a management benchmark.
GIS regional growth rate (adjusted for foreign exchange impact)
Japan1%
North America20%
Europe20%
China5%
Asia and Oceania14%
SIS regional growth rate (adjusted for foreign exchange impact)
Japan-6%
North America14%
Europe3%
China-6%
Asia and Oceania-6%
GIS subsegment growth rate (adjusted for foreign exchange impact)
Gastrointestinal endoscopes12%
Gastrointestinal procedure devices27%
Healthcare Services13%
SIS subsegment growth rate (adjusted for foreign exchange impact)
Urology16%
Respiratory medicine18%
Surgical endoscopy7%
Other therapeutic areas-22%
Segment results
GIS
Net Sales
352,982 Millions of yen+15.0%
Operating profit
98,784 Millions of yen+84.8%
SIS
Net Sales
156,560 Millions of yen+6.4%
Operating profit
3,159 Millions of yen
Corporate and eliminations
Net Sales
51 Millions of yen
Operating loss
-16,981 Millions of yen
Financial targets
Equity ratio49.6% (as of 30 September 2026)
Number of employees
Number of Employees27,450 people (including 16,743 overseas)
Change during the periodDown 688 people from 28,138 at the end of March 2026
Capital expenditures
¥49,812 million capital expenditures for the first six months
| Item | Details |
|---|---|
| Document type | Supplementary Materials to the Earnings Summary |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | 509,593 Millions of yen (YoY +12.2%) |
| Operating profit | 84,962 Millions of yen (YoY +84.2%) |
| Net income | 52,146 Millions of yen (YoY +78.7%) |
| Gross Profit Margin | Rate 68.3% / Year-on-year change (points) 3.1 |
| Operating profit margin | Rate 16.7% / Year-on-year change (points) 6.5 |
| Selling, general and administrative expenses | 251,126 Millions of yen |
| Results for the three months of the current quarter | Net Sales 269,193 Millions of yen / Operating profit 56,011 Millions of yen / Pretax profit 55,045 Millions of yen / Net income 33,044 Millions of yen |
| Full-year earnings forecast | Net Sales ¥1,064,500–¥1,076,000 million / Operating profit ¥155,000–¥167,500 million / Adjusted operating profit ¥186,500–¥199,000 million / Pretax profit ¥150,000–¥162,500 million / Net income ¥103,500–¥112,000 million / EBITDA ¥223,000–¥235,500 million |
| Segment results | GIS Net Sales 352,982 Millions of yen (YoY +15.0%) / Operating profit 98,784 Millions of yen (YoY +84.8%) / SIS Net Sales 156,560 Millions of yen (YoY +6.4%) / Operating profit 3,159 Millions of yen / Corporate and eliminations Net Sales 51 Millions of yen / Operating loss -16,981 Millions of yen |
| Breakdown of Factors Affecting the Change | Foreign exchange impact on revenue 41,867 Millions of yen / Foreign exchange impact on operating profit 14,889 Millions of yen |
| Key KPIs | GIS regional growth rate (adjusted for foreign exchange impact) Japan 1% / North America 20% / Europe 20% / China 5% / Asia and Oceania 14% / SIS regional growth rate (adjusted for foreign exchange impact) Japan -6% / North America 14% / Europe 3% / China -6% / Asia and Oceania -6% / GIS subsegment growth rate (adjusted for foreign exchange impact) Gastrointestinal endoscopes 12% / Gastrointestinal procedure devices 27% / Healthcare Services 13% / SIS subsegment growth rate (adjusted for foreign exchange impact) Urology 16% / Respiratory medicine 18% / Surgical endoscopy 7% / Other therapeutic areas -22% |
| Number of employees | Number of Employees 27,450 people (including 16,743 overseas) / Change during the period Down 688 people from 28,138 at the end of March 2026 |
| Assumptions Underlying the Business Outlook | Average exchange rate US$1=¥155.00, €1=¥181.00, CNY1=¥22.50 |
| Financial targets | Equity ratio 49.6% (as of 30 September 2026) |
| Capital expenditures | ¥49,812 million (capital expenditures for the first six months) |
Items this document does not state (14)
Ordinary incomeProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The materials state that the fiscal year 2027 second-quarter and first-half results, as well as the full-year forecast, include the impact of a temporary US tariff refund. They also present the impact of foreign exchange movements and growth rates by region and subsegment, but do not explain in narrative form why the full-year forecast was raised.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.